Holding website  

  • About Us
    • What we do
      • Strategic Approach
    • Management Team
    • Collaboration & Partnering
    • Investors
    • Careers
      • Open Positions
        • Head of Medical Affairs
    • Privacy
  • APR Products
    • Prescription Healthcare Products
      • PKU GOLIKE® Family
      • Nexodyn® – Advanced Wound Care
        • Tehclo Technology
      • Diclofenac Immediate Release
        • Immediate Release Technology
        • Diclofenac 50 mg products
      • Ondansetron ODF
        • ODF Technology
        • Ondansetron ODF products
      • APR TD011 – Epidermolysis Bullosa
        • Tehclo Technology
      • APR TD012 – Hailey Hailey Disease
        • Tehclo Technology
      • APR 1204 – Ocular Surface Diseases
        • Tehclo Technology
      • Exelya®
        • Exelya®
        • Tehclo Technology
    • Consumer Healthcare Products
      • Acute Pain
        • Diclofenac 25 mg products
      • Healthy Aging – SwitzAge™
      • Pediatric
        • Halykoo
    • Therapeutical Areas
      • Inherited Metabolic Disorders
        • What is PKU (Phenylketonuria)?
      • Advanced Wound Care
        • Unmet Medical Need
      • Cancer Supportive Care
        • Nausea and vomiting
        • Oncodermatology
      • CNS (migraine)
      • Rare Dermatological Diseases
        • Epidermolysis Bullosa
        • Hailey Hailey Disease
      • Eye laser surgery
    • Pipeline
  • Our Services
    • Solid Dosage Forms
      • Oral Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Oral Nutraceuticals
        • Integrated project development
        • Project design planning
      • Oral Medical Devices
        • Integrated project development
        • Project design planning
    • Non-Solid Dosage Forms
      • Topical Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Topical Dermocosmetics
        • Integrated project development
        • Project design planning
      • Topical Medical Devices
        • Integrated project development
        • Project design planning
    • Analytical Services
    • Certifications
  • Media
    • Presentations
    • Press Releases
  • Contacts
    • Location
    • Vigilance
    • APR LAB

Discover who we are and our partners global network, as well as learn more about our people.

Learn more about our products and how they provide innovative solutions for patiens' unmet needs.

Discover our capabilities in project design services.

Find information such as website news, press releases and event presentations.

Get in touch with us to set up a meeting or propose your cooperation.

 

Holding website  

  • About Us
    • What we do
      • Strategic Approach
    • Management Team
    • Collaboration & Partnering
    • Investors
    • Careers
      • Open Positions
        • Head of Medical Affairs
    • Privacy
  • APR Products
    • Prescription Healthcare Products
      • PKU GOLIKE® Family
      • Nexodyn® – Advanced Wound Care
        • Tehclo Technology
      • Diclofenac Immediate Release
        • Immediate Release Technology
        • Diclofenac 50 mg products
      • Ondansetron ODF
        • ODF Technology
        • Ondansetron ODF products
      • APR TD011 – Epidermolysis Bullosa
        • Tehclo Technology
      • APR TD012 – Hailey Hailey Disease
        • Tehclo Technology
      • APR 1204 – Ocular Surface Diseases
        • Tehclo Technology
      • Exelya®
        • Exelya®
        • Tehclo Technology
    • Consumer Healthcare Products
      • Acute Pain
        • Diclofenac 25 mg products
      • Healthy Aging – SwitzAge™
      • Pediatric
        • Halykoo
    • Therapeutical Areas
      • Inherited Metabolic Disorders
        • What is PKU (Phenylketonuria)?
      • Advanced Wound Care
        • Unmet Medical Need
      • Cancer Supportive Care
        • Nausea and vomiting
        • Oncodermatology
      • CNS (migraine)
      • Rare Dermatological Diseases
        • Epidermolysis Bullosa
        • Hailey Hailey Disease
      • Eye laser surgery
    • Pipeline
  • Our Services
    • Solid Dosage Forms
      • Oral Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Oral Nutraceuticals
        • Integrated project development
        • Project design planning
      • Oral Medical Devices
        • Integrated project development
        • Project design planning
    • Non-Solid Dosage Forms
      • Topical Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Topical Dermocosmetics
        • Integrated project development
        • Project design planning
      • Topical Medical Devices
        • Integrated project development
        • Project design planning
    • Analytical Services
    • Certifications
  • Media
    • Presentations
    • Press Releases
  • Contacts
    • Location
    • Vigilance
    • APR LAB

ABOUT US

APR Applied Pharma Research s.a. (APR), as part of the Relief Group of companies, is a Swiss company dedicated to providing patients suffering from rare diseases with innovative treatments that make a real difference in their life.

Our focus, as a Swiss biopharma company is the identification, development and commercialization of best-in-class, patent protected products in selected rare and ultra-rare disease areas.

Optimizing a product's therapeutic potential by developing and applying advanced patented pharma technologies as well as through proprietary delivery systems or novel dosage forms is our way to add value to the rare diseases field.

Our Services

Collaborations & Partnering

APR Applied Pharma Research

Has a proven track record in developing branded and patented products worldwide.
Counts on a balanced mix of marketed, revenue-generating products and a compelling pipeline
of innovative products in rare indications
at different stages of development, with main focus
on rare recessive metabolic diseases, rare dermatological diseases and ocular diseases.
Offers late-stage licensing opportunities for internally developed products.
Provides a complete and vertically integrated range of contract R&D services - from formulation
to regulatory support on an international basis.


Pharmaceutical Research and development
Our Network Worldwide

The company is headquartered in Switzerland. With our extensive network of commercial partners, APR's products are distributed in more than 70 countries worldwide, whereas the Company distributes and markets directly with its own sales and marketing organization a selection of our products in rare diseases field in selected countries of Europe.

Collaborations
& Partnering

Our Services

Contacts APR Products
APR 2015 all rights reserved | About us | APR Products | Our services | News & Events | Contact | Privacy policy | Cookie policy | Sitemap